

25 June 2024

The Manager Companies  
ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

Dear Madam,

## BIOTRON CLINICAL TRIAL RESULTS WEBINAR

### Investor Webinar 11am AEST Wednesday 26 June, 2024

Register using this link:

[https://us06web.zoom.us/webinar/register/WN\\_8uQjMZ3eSxSGyKyjmHePaA](https://us06web.zoom.us/webinar/register/WN_8uQjMZ3eSxSGyKyjmHePaA)

*Participants may submit questions during registration or during the session*


- **BIT225-011 Phase 2 HIV trial met primary objectives in patients who have not achieved full immune reconstitution despite long-term suppressive antiretroviral treatment**
  - BIT225 was safe and generally well tolerated with no deaths or drug-related serious adverse events
  - All trial patients maintained viral suppression throughout the study with statistically significant improvements in immune markers, in line with previous trials
- **BIT225-010 Phase 2 HIV trial in treatment-naïve patients met primary objectives**
  - Suggests unique effect beyond current standard-of-care antiretroviral drugs
- **Detailed results analysis for BIT225-012 trial in Sars-CoV-2 underway**

Biotron CEO and Managing Director, Dr Michelle Miller, and Chief Medical Officer, Dr Stephen Becker, will host a webinar 11am AEST 26 June 2024 to update investors on the positive results from two Phase 2 trials for BIT225 in HIV patients.

The outcomes are in line with previous trials and suggests BIT225 has a unique immune-modifying effect when used with cART.

Interested participants are invited to register using the link above.

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn12226